In Vitro Activity of Imipenem/Relebactam Alone and in Combination Against Cystic Fibrosis Isolates of Mycobacterium abscessus
These findings suggest that imipenem/relebactam may offer a significant advancement in the management of MABS infections in PwCF. The promising efficacy of multidrug regimens combining imipenem/relebactam with agents like cefoxitin, azithromycin, moxifloxacin, clofazimine, and rifabutin highlights potential therapeutic strategies.
Authors
- Suzy Kim (ORCID: https://orcid.org/0000-0001-7161-8340)
- Paul M. Beringer (ORCID: https://orcid.org/0000-0002-3744-3310)
- Madeline Sanders
- Aditi Shinde
- Eric Quach
- Danielle Fletcher-Williams
Institutions
- University of Southern California (US)
Publication Details
- Journal
- Antibiotics
- Published
- 2025-05-10
- DOI
- https://doi.org/10.3390/antibiotics14050486
- Citations
- 1
- Primary Topic
- Mycobacterium research and diagnosis
- Type
- article
- Field-Weighted Citation Impact
- 1.35
Funders
- Merck
- National Jewish Health
- National Institute of Dental and Craniofacial Research